MedTrace Logo

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

NCT04957160 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 281

Last updated 2024-12-17

No results posted yet for this study

Summary

This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination therapy and progressed to a 2L treatment with particular focus to understanding where cabozantinib is prescribed after 1L IO containing combination therapy.

Conditions

  • Advanced Renal Cell Carcinoma (aRCC)

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2022-06-15
Completion
2022-06-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04957160 on ClinicalTrials.gov